We found that treatment with siRNA targeting MMP9, but not the control siRNA, suppressed the ability of Wnt5a to enhance chemokine-directed CLL cell invasion (Fig. 3B). The gene discussed is MMP9; the disease is B-cell chronic lymphocytic leukemia.